CIBC Private Wealth Group
PCRX icon

CIBC Private Wealth Group’s Pacira BioSciences PCRX Stock Holding History

CIBC Private Wealth Group’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$259 Buy
+10
New +$238 ﹤0.01% 3168
2025
Q2 		– Sell
-83
Closed -$2.18K – 3253
2025
Q1 		$2.18K Buy
+83
New +$1.99K ﹤0.01% 2665
2024
Q3 		– Sell
-3,222
Closed -$66.4K – 3255
2024
Q2 		$66.4K Sell
3,222
-804
-20% -$22.9K ﹤0.01% 1563
2024
Q1 		$117K Buy
+4,026
New +$124K ﹤0.01% 1328
2018
Q3 		– Sell
-19
Closed -$1K – 1491
2018
Q2 		$1K Hold
19
– – ﹤0.01% 1904
2018
Q1 		$1K Hold
19
– – ﹤0.01% 1871
2017
Q4 		$1K Buy
+19
New +$753 ﹤0.01% 1876

Other funds holding PCRX

BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $127B AUM 43.98% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $761B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return